Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyCapital Bluecross Maze Procedures Coverage Update …
    Ask Trek AI about this page
    ModifiedCapital BluecrossPolicy MP 2.083

    Open and Thoracoscopic Approaches to Treat Atrial Fibrillation and Atrial Flutter (Maze and Related Procedures)

    Customize your policy alerts

    Sign up for Capital Bluecross Policy MP 2.083 alerts

    Get alerted when Policy MP 2.083 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of open and thoracoscopic (including minimally invasive, hybrid, and modified maze) surgical approaches to treat atrial fibrillation and atrial flutter for members of Capital BlueCross products to which the policy applies.

    Policy Summary
    PayerCapital Bluecross
    PolicyOpen and Thoracoscopic Approaches to Treat Atrial Fibrillation and Atrial Flutter (Maze and Related Procedures)
    Policy CodePolicy MP 2.083
    Change TypeMaterial coverage and code updates (investigational reclassification and ICD-10 additions)
    Effective DateJul 1, 2026
    Last ReviewFeb 12, 2026
    Next Review DateFeb 12, 2026
    Key ActionConfirm benefit coverage and obtain prior authorization when performing concomitant maze procedures during cardiopulmonary bypass with cardiac surgery.
    SourceLink
    POLICY UPDATE CHANGES

    Added ICD-10 diagnosis codes I48.91 and I48.92.

    Maze/modified Maze without concomitant cardiac surgery and cardiopulmonary bypass changed from medically necessary to investigational.

    Hybrid ablation and minimally invasive, off-pump Maze procedure were previously changed from investigational to medically necessary (07/20/2020) and later policy history entries updated status and references.

    02/12/2026 Retirement Review recorded.

    90%Cox maze success
    5 RCTs

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Hybrid RCTs
    9% vs 6%CEASE-AF major comps
    insufficientEvidence sufficiency
    multipleCovered diagnoses
    I48.91,I48.92ICD-10 added

    Coverage Criteria and Policy Stance

    Concomitant open or modified maze with cardiac surgery

    Covered when ALL of the following are met:

    Concomitant Maze Criteria: Patient is undergoing cardiac surgery with cardiopulmonary bypass AND a Cox maze or modified maze procedure is performed on a non-beating heart during bypass

    Document symptomatic atrial fibrillation or atrial flutter; randomized trials and comparative studies demonstrate added benefit (reduced atrial arrhythmias) with minimal additional risks when performed concomitantly, particularly with mitral valve surgery.

    Stand-alone minimally invasive (off-pump thoracoscopic) maze procedures

    Policy stance and rationale:

    Thoracoscopic Stand-alone Maze: Minimally invasive, off-pump (thoracoscopic or mini-thoracotomy) stand-alone maze procedures for treatment of atrial fibrillation or atrial flutter

    Considered investigational due to insufficient evidence to support a general conclusion regarding net health outcome; some RCTs report higher 1-year freedom from AF but evidence is inconsistent with regard to harms and overall benefit.

    Hybrid thoracoscopic + endocardial ablation

    Policy stance and rationale:

    Hybrid Approach: Hybrid ablation combining thoracoscopic epicardial and percutaneous endocardial (endovascular) ablation in the same patient for atrial fibrillation or flutter

    Considered investigational as evidence is insufficient to conclude an overall net health benefit: trials show increased AF-free survival but also increased periprocedural adverse events; lesion sets and techniques are heterogeneous and not standardized.

    Hybrid thoracoscopic and endocardial ablation (when not undergoing cardiac surgery with bypass)

    Evidence summary and coverage stance for hybrid thoracoscopic and endocardial ablation in symptomatic, drug‑resistant AF/flutter when not performed with concomitant cardiac surgery and bypass:

    Evidence findings: Randomized and nonrandomized studies report increased rates of AF-free survival and reduced need for cardioversion with hybrid procedures compared with standard endocardial ablation, but also report increased periprocedural adverse events. The largest RCT (CEASE-AF) reported composite major complications at 1 year of 9% with hybrid versus 6% with standard ablation. Surgical lesion sets varied across studies and have not been standardized.

    Overall evidence judged insufficient to determine a net health outcome benefit; STS guidelines may support surgical treatment in selected circumstances.

    General surgical approaches (open or thoracoscopic Maze and related procedures)

    Overall evidence appraisal for open and thoracoscopic surgical ablation approaches:

    Evidence conclusion: Comparative and noncomparative studies show higher rates of freedom from atrial arrhythmias for some surgical approaches, but heterogeneous study designs, inconsistent adverse-event reporting, and variable lesion sets prevent definitive conclusions about superiority or net health benefit. Evidence is insufficient to determine that specific thoracoscopic or hybrid approaches consistently improve net health outcomes.

    Individual factors (prior treatments, likelihood of maintaining sinus rhythm, complication risk, anticoagulation status, and patient preference) should inform decision-making.

    Policy history / coverage-status changes

    Policy history notes changes in coverage status over time; specific coverage criteria are located in other sections of the full policy.

    policy_history_changes: Policy history includes: reclassification of hybrid ablation and minimally invasive off‑pump Maze from investigational to medically necessary (07/20/2020); addition of ICD-10 codes I48.91 and I48.92 (06/11/2024); reclassification of Maze/modified Maze without concomitant cardiac surgery and cardiopulmonary bypass to investigational (12/5/2025); and a retirement review entry (02/12/2026).

    Coverage criteria details remain in the policy body; these history entries explain prior changes in coverage stance.

    An open maze or modified maze procedure performed on a non‑beating heart during cardiopulmonary bypass is considered medically necessary only when performed concomitantly with cardiac surgery. The policy distinguishes these concomitant procedures from stand‑alone, off‑pump approaches; when performed with cardiac surgery and bypass, the Cox maze or modified maze may be appropriate to treat symptomatic atrial fibrillation or atrial flutter and is supported by the policy language referencing benefits in the surgical setting.

    Investigational; not covered for Maze procedures performed without cardiopulmonary bypass and without concomitant cardiac surgery. The policy explicitly designates Maze procedures done outside the context of concomitant cardiac surgery with bypass as investigational and therefore not covered.

    Coverage status updated: Maze/modified Maze without concomitant cardiac surgery and cardiopulmonary bypass is listed as investigational as of 12/5/2025 per the policy history entry.

    Stand‑alone minimally invasive off‑pump maze procedures (including thoracoscopic or mini‑thoracotomy approaches), hybrid ablation (combined thoracoscopic epicardial and percutaneous endocardial), and open maze performed without concomitant cardiac surgery are labeled investigational in this policy. The policy notes insufficient evidence to support general conclusions about net health outcome benefits for these standalone or hybrid approaches.

    The evidence for thoracoscopic/hybrid approaches is mixed: randomized and nonrandomized studies report higher rates of AF‑free survival but also an increased risk of periprocedural adverse events (for example, the largest RCT reported a composite major complication rate of 9% vs 6% for hybrid versus standard ablation). Because of heterogeneous lesion sets, inconsistent adverse‑event reporting, and uncertainty about net clinical benefit, these thoracoscopic and hybrid approaches are considered investigational.

    Overall, the policy concludes that the available evidence is insufficient to determine that certain thoracoscopic or hybrid approaches improve net health outcome. Studies demonstrate higher arrhythmia‑free rates but are limited by inconsistent assessment of harms, varied surgical lesion sets, and heterogeneous outcome reporting, preventing definitive conclusions about safety and net benefit.

    Coding: Procedure and Diagnosis Codes

    Regulatory / Device listings (informational)mixed
    FDA 510(k) devices listedSelect radiofrequency and cryoablation systems cleared for cardiac tissue ablation (product code OCL). Examples: EPi-Sense Guided Coagulation System; Medtronic DiamondTemp System; Cobra Fusion Ablation System; Medtronic Cardioblate systems; Cardima Ablation System; Epicor Medical Ablation System; Isolator Systems; Estech COBRA Cardiac Electrosurgical Unit; Coolrail Linear Pen; Numeris Guided Coagulation System with VisiTrax; EPi-Sense Guided Coagulation System with VisiTrax; Cryocare Cardiac Surgery System; SeedNet/SurgiFrost XL; Isis cryosurgical unit; Arctic Front Advance series)
    Procedure Codes (referenced)mixed
    unspecifiedProcedure codes referenced in policy (specific CPT/HCPCS codes not listed in provided document chunks).
    Covered Diagnosis ICD-10 CodesICD-10Covered
    I48.0Paroxysmal atrial fibrillation
    I48.1Persistent atrial fibrillation
    I48.11Longstanding persistent atrial fibrillation
    I48.19Other persistent atrial fibrillation
    I48.20Chronic atrial fibrillation, unspecified
    I48.21Permanent atrial fibrillation
    I48.3Typical atrial flutter
    I48.4Atypical atrial flutter
    I48.91Unspecified atrial fibrillation
    I48.92Unspecified atrial flutter
    Added ICD-10 CodesICD-10
    I48.91Unspecified atrial fibrillation
    I48.92Unspecified atrial flutter

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization for concomitant Maze with cardiac surgery

    Concomitant open or modified maze performed during cardiopulmonary bypass with concomitant cardiac surgery may be considered medically necessary; confirm benefit coverage and obtain any required prior authorization per the member's specific product rules.

    • Medically necessary when performed during cardiopulmonary bypass with concomitant cardiac surgery.
    • Verify and follow the member's product-specific prior authorization procedures before scheduling.
    Prior Authorization

    Preauthorization may be required

    Services described in this policy may require preauthorization; benefit determinations should be based on the applicable health benefit plan language.

    • Medical policies do not describe benefits — consult the member's health benefit plan for preauthorization requirements.
    • Contact Capital BlueCross Provider Services or Member Services for plan-specific instructions.

    Background and Clinical Context

    Atrial fibrillation (AF) is a supraventricular tachyarrhythmia caused by disorganized atrial activation often triggered by myocardial extensions from the pulmonary veins. Surgical ablation approaches, including the classic Cox maze and modified maze variants, aim to interrupt aberrant conduction pathways to restore sinus rhythm. Minimally invasive thoracoscopic and hybrid techniques have been developed to reduce invasiveness, but they differ in lesion sets, procedural invasiveness, and reported complication profiles.

    Definitions and Procedural Descriptions

    inv-30: Hybrid ablation — combined thoracoscopic epicardial + percutaneous endocardial
    DefinitionA combined thoracoscopic epicardial and percutaneous endocardial approach performed in the same patient, often in a single setting, intended to achieve more complete ablation by combining epicardial (thoracoscopic) and endocardial (percutaneous) techniques.
    Procedure sequenceTypically begins with thoracoscopic epicardial ablation followed by percutaneous electrophysiology study and endocardial ablation; endocardial ablation is often performed immediately after thoracoscopy but may be staged on separate days.
    RationaleCombines strengths of epicardial and endocardial approaches to perform more complete lesion sets and minimize incomplete ablation lines inherent to each technique alone.
    Limitations notedThoracoscopic epicardial ablation may not access posterior structures fully; endocardial ablation alone can leave incomplete lines requiring repeat procedures—hybrid seeks to address these gaps.
    inv-31: Modified maze procedure — energy sources and lesion sets
    Policy Summary
    PayerCapital Bluecross
    PolicyOpen and Thoracoscopic Approaches to Treat Atrial Fibrillation and Atrial Flutter (Maze and Related Procedures)
    Policy CodePolicy MP 2.083
    Change TypeMaterial coverage and code updates (investigational reclassification and ICD-10 additions)
    Effective DateJul 1, 2026
    Last ReviewFeb 12, 2026
    Next Review DateFeb 12, 2026
    Key ActionConfirm benefit coverage and obtain prior authorization when performing concomitant maze procedures during cardiopulmonary bypass with cardiac surgery.
    SourceLink
    On This Page
    Coverage Criteria and Policy StanceCoding: Procedure and Diagnosis CodesProvider Requirements, Prior Authorization, and DocumentationBackground and Clinical ContextDefinitions and Procedural Descriptions
    Prior Authorization

    Verify prior authorization when coverage status or codes change

    Prior authorization requirements are implied by recent coverage-status changes and code updates; providers must verify prior authorization per payer procedures when submitting claims for Maze or hybrid ablation services.

    • Policy history documents reclassifications and added diagnosis codes that may affect authorization workflows.
    • Confirm PA requirements with the member's plan before performing investigational or reclassified procedures.
    Documentation Required

    Document trial of ≥1 Class I or III antiarrhythmic

    Document prior medication trials showing intolerance or failure of at least one Class I or III antiarrhythmic agent, consistent with the 2017 Expert Consensus indication for surgical ablation.

    • Include which Class I or III agent(s) were used, duration of therapy, and reason for discontinuation (intolerance or lack of efficacy).
    • Attach supporting clinical notes when submitting prior authorization or claims.
    Documentation Required

    Documentation and product applicability (reserved item)

    See policy for applicable documentation expectations and product applicability; providers should supply supporting clinical documentation when submitting for review.

    • Provide clinical notes, operative reports, prior treatments, and medication trial documentation with PA or claims submissions.
    • If the member's product excludes this policy, follow the benefit plan's alternative coverage process.
    Step Therapy

    No explicit step therapy in policy — confirm plan requirements

    This policy does not specify a formal step-therapy protocol; confirm whether the member's benefit plan imposes any step-therapy or prior-treatment requirements.

    • Policy history shows prior consensus reviews but no explicit step-therapy rules in the policy text.
    • Verify benefit- or product-specific requirements that could function as step therapy before authorization.
    Note

    Confirm member product/benefit applicability

    Confirm the member's product and benefit design before proceeding; this policy applies only to certain Capital BlueCross programs and products and some programs/products are excluded.

    • Check whether the member's plan (for example, FEP PPO) follows a different medical policy manual.
    • Contact Capital BlueCross for product-specific applicability and exclusions.
    Billing Rule

    Plan and preauthorization contact information

    Consult the member's health benefit plan for coverage, limits, and preauthorization details; contact Capital BlueCross Provider Services or Member Services for plan-specific preauthorization instructions.

    • Medical policies do not describe benefits; the member's health benefit plan governs coverage and preauthorization.
    • Use the contact channels specified by the member's plan to obtain prior authorization details.
    Documentation Required

    Provide documentation supporting indications with PA/claims

    When submitting prior authorization requests or claims, include documentation that supports the indication and any relevant policy-history changes (e.g., code additions or coverage reclassifications).

    • Supply operative reports, clinical indications, medication trial records, and rationale for the procedure given shifting coverage statuses.
    • Documentation may affect adjudication for procedures with recent policy changes.
    Denial Risk

    Investigational procedures — denial risk if billed as medically necessary

    Procedures designated investigational — including stand-alone minimally invasive off-pump maze, hybrid ablation, and open maze without concomitant cardiac surgery — are not supported as medically necessary and are at risk for denial when billed as such.

    • Stand‑alone minimally invasive (off‑pump) maze procedures and hybrid thoracoscopic + endocardial ablation are considered investigational.
    • Open maze or modified maze performed without concomitant cardiac surgery during bypass is considered investigational.
    Note

    Benefit plan governs coverage

    Benefit determinations are based on the member's specific health benefit plan; the presence of this medical policy does not guarantee coverage for a given member or service.

    • Medical policies do not constitute a description of benefits — the member's plan language governs covered services, exclusions, limits, and prior authorization requirements.
    • Always confirm coverage with the member's plan before scheduling services.
    Denial Risk

    Investigational procedure — explicit denial risk

    Procedures designated investigational (for example, Maze/modified Maze without concomitant cardiac surgery and cardiopulmonary bypass as of 12/5/2025) may be denied as investigational if submitted as medically necessary.

    • Policy history records the 12/5/2025 reclassification of Maze without concomitant cardiac surgery to investigational.
    • Expect denials for investigational procedures unless the member's benefit plan explicitly covers them.
    DefinitionSurgical ablation using energy sources (radiofrequency, cryo, ultrasound, microwave) to create lesion sets analogous to the cut-and-sew Cox maze, often with less extensive lesions such as pulmonary vein isolation and left atrial appendage exclusion.
    Energy sourcesRadiofrequency is most commonly applied; other sources include cryoablation and high-intensity ultrasound (and historically microwave).
    Lesion setsMay range from limited pulmonary vein isolation to more extensive linear ablations of the left and/or right atrium and ganglionic plexi ablation; left atrial reduction may be performed for enlargement.
    Clinical contextConsidered variations of the classic Cox maze and grouped under 'modified maze' for policy purposes; used to avoid the incisional 'cut-and-sew' technique by creating transmural lesions with energy devices.
    inv-32: ATRIAL FLUTTER — definition
    DefinitionA cardiac arrhythmia marked by rapid (about three hundred beats per minute) regular atrial beating and, usually, a regular ventricular response.
    Chamber involvedAtria (upper chambers of the heart).
    Clinical implicationOften presents with regular ventricular response and is distinguished from atrial fibrillation by its organized atrial activity.
    inv-33: AV NODE — short definition
    DefinitionAn area of specialized cardiac muscle that receives the cardiac impulse from the sinoatrial (SA) node and conducts it to the AV bundle and then to the Purkinje fibers and ventricles; located in the septal wall between the left and right atria.
    FunctionConduction delay and coordination between atria and ventricles, facilitating timed ventricular activation.
    Anatomic noteLocated in the septal wall between the left and right atria.
    inv-34: SINOATRIAL (SA) NODE — short definition
    DefinitionA specialized group of cardiac muscle cells in the wall of the right atrium at the entrance to the superior vena cava that depolarize spontaneously and rhythmically to initiate normal heartbeats.
    RolePrimary cardiac pacemaker that initiates the impulse transmitted through the atria to the AV node.
    LocationWall of the right atrium near the superior vena cava entrance.
    inv-35: Hybrid/Convergent ablation — combined epicardial + endocardial approach
    DefinitionA combined epicardial and endocardial ablation approach (often termed convergent or hybrid) that pairs surgical epicardial thoracoscopic ablation with percutaneous endocardial catheter ablation to treat persistent and long-standing persistent atrial fibrillation.
    Indications in literatureDescribed for persistent and long-standing persistent atrial fibrillation and evaluated in randomized trials and observational studies (e.g., CONVERGE).
    GoalTo achieve more complete transmural lesion sets by addressing limitations of epicardial-only or endocardial-only techniques.
    inv-36: Minimally invasive/thoracoscopic Maze — thoracoscopic PV isolation & lesion sets
    DefinitionThoracoscopic or video-assisted surgical pulmonary vein isolation and Maze lesion sets performed via minimally invasive approaches on the beating heart, often using epicardial ablation and sometimes including left atrial appendage exclusion.
    Approach characteristicsPerformed off-pump (beating heart) via mini-thoracotomy or total thoracoscopy with video assistance; does not enter the heart cavity and uses epicardial lesion sets.
    Lesion variabilityLesion sets vary from limited pulmonary vein isolation to more extensive box lesions and ganglionic plexi ablation; reports include standardized totally thoracoscopic box lesion techniques and other series.